

Endothelial dysfunction in COVID-19 patients assessed with Endo-PAT2000

Giuliana Cimino, Enrico Vizzardi, Emiliano Calvi, Edoardo Pancaldi, Greta Pascariello, Nicola Bernardi, Angelica Cersosimo, Ludovica Amore, Riccardo M. Inciardi, Riccardo Raddino, Marco Metra

Department of Medical and Surgical Specialties, Institute of Cardiology, University of Brescia, Italy

Abstract

It has been widely reported that the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) attaches human cells by

using the Angiotensin Converting Enzyme 2 (ACE2) receptor [1], which is expressed in several organs, including the endothelial cells [2]. Whether vascular impairment described during coronavirus disease 2019 (COVID-19) infection is primarily due to the direct involvement of the endothelial cells by the virus or secondarily to the inflammatory host response is currently unknown, but there is evidence that SARS-CoV-2 can directly infect human blood vessel [3]. Recently, Varga and colleagues, described autopsy findings from three patients who died from COVID-19, showing direct viral infection of the endothelium systemic and endotheliitis with proliferation of lymphocytes and macrophages, and loss of integrity of the endothelial monolayer [4]. These patients, however, were affected by concomitant cardiovascular disease such as hypertension, diabetes, obesity, and coronary artery disease, underlying a potential pre-existing endothelial dysfunction.

Correspondence: Enrico Vizzardi, MD, Institute of Cardiology, Spedali Civili, Piazzale Spedali Civili 1, 25123 Brescia, Italy. E-mail: vizzardi72@gmail.com

Key words: Endothelial dysfunction; endotheliitis; inflammatory state; COVID-19

Acknowledgements: All authors have acknowledged and approved authorship.

Conflict of interest: The authors declare that they have no competing interests, and all authors confirm accuracy.

Ethics approval and consent to participate: this study has been approved by the Institutional Ethics Committee. Informed consent was obtained from the patients included in this study.

Availability of data and materials: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Contributions: EV, MM, study design; GC, patients' enrolment data collection and patients' follow-up; EC, EP, GP, NB, AC, LA, contributed to data collection; RR, RMI, contributed to data analysis; EV, GC, manuscript drafting. All the authors have read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Conference presentation: This work was presented as an abstract at the SIC Congress 2020.

Received for publication: 23 January 2022.
Accepted for publication: 27 January 2022.

Publisher's note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

©Copyright: the Author(s), 2022

Licensee PAGEPress, Italy

Monaldi Archives for Chest Disease 2022; 92:2213

doi: 10.4081/monaldi.2022.2213

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial International License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Materials and Methods

We therefore aimed to demonstrate in vivo the presence of endothelial dysfunction in COVID-19 patients without cardiovascular risk factors or pre-existing cardiac conditions. We used the Endo-PAT 2000, a device able to measure endothelial vasodilation function in a rapid and non-invasive way [5]. The device records endothelium-mediated changes in the digital pulse waveform known as the Peripheral Arterial Tone (PAT) signal, measured with a pair of plethysmographic probes situated on the index finger of both patient's hands. Endothelium-mediated changes in the PAT signal are elicited by creating a downstream hyperemic response, induced by blood flow occlusion in the brachial artery for 5 minutes using an inflatable cuff on one arm. The response to reactive hyperemia is evaluated automatically by the device, and a PAT ratio is calculated using the post- and pre-occlusion PAT values relative to the occluded arm (compared to the measurements from the contralateral arm, which serves as control for non-endothelial dependent systemic effects). The Reactive Hyperemia Index (RHI) is then calculated as the ratio of Pulse Wave Amplitude (PWA) measured during the 60-second period after cuff deflation divided by the average PWA measured before cuff inflation; RHI values below 1.67 are suggestive of endothelial dysfunction.

Results

We evaluated six patients with laboratory-confirmed SARS-CoV-2 infection with a mean age of 75.8 years. Five of them were female (83.3%); the average mean arterial pressure was 87 mmHg (normal values 70-110 mmHg). Blood sample tests revealed an inflammatory state in all patients, with high plasma levels of C-




Figure 1. EndoPAT test performed on a 63-year-old female COVID-19 patient without cardiovascular risk factors or other diseases. The graph does not show any significant difference in PAT Signal increase after cuff release in the occluded arm (when compared with control arm), suggesting an endothelial dysfunction as confirmed by a RHI value well below the cutoff (1.13).

reactive protein, fibrinogen, ferritin, LDH, and D-dimer. Overall, four patients were positive for endothelial dysfunction, with RHI values between 1.13-1.56 (average value 1.32, normal values >1.67) (Figure 1); in one of the two negative patients the reported RHI value was slightly above the cutoff (1.72).

Discussion

Our findings confirm that COVID-19 patients are at higher risk of developing endothelial dysfunction. In addition, our results demonstrate that endothelial impairment may occur even in the absence of cardiovascular risk factors.

Endothelial dysfunction may play a pivotal role in the pathophysiology of the infection process and may identify a subset of patient at a higher risk of worse outcome. In a small series of patients who died from COVID-19, severe endothelial injury associated with intracellular virus detection, disruption of endothelial cell membranes, widespread pulmonary vascular thrombosis and occlusion of alveolar capillaries with significant new vessel growth, was observed [6]. Early recognition of endothelial impairment at an early stage of the disease, before the development of the mentioned histological complications, appears critical. Whether the evidence of endothelial dysfunction, through noninvasive approaches, can predict worse clinical outcomes or higher risk of thromboembolic events needs to be proven by recruiting a larger

number of affected patients. Nevertheless, our results contribute to the knowledge of the pathophysiological mechanisms related to COVID-19 infection.

References

- Tomasoni D, Italia L, Adamo M, et al. COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. *Eur J Heart Fail* 2020;22:957-66.
- Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation* 2005;111:2605-10.
- Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. *Cell* 2020;181:905-13.
- Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 2020;395:1417-8.
- Axtell AL, Gomari FA, Cooke JP. Assessing endothelial vasodilator function with the Endo-PAT 2000. *J Vis Exp* 2010;44:e2167.
- Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. *N Engl J Med* 2020;383:120-8.